Aberrant mTOR signaling impairs whole body physiology

Aberrant mTOR signaling impairs whole body physiology
Activated mTORC1 signaling (top) correlates with increased FGF21 expression (below) in human liver tumor. Credit: University of Basel, Biozentrum

The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer. In the current issue of the journal Proceedings of the National Academy of Sciences, researchers from the Biozentrum of the University of Basel describe how aberrant mTOR signaling in the liver not only affects hepatic metabolism but also whole body physiology.

The protein mTOR regulates cell growth and metabolism and thus plays a key role in the development of human disorders. In the cell, this is found in two structurally and functionally distinct protein complexes called mTORC1 and mTORC2. In a recent study, the research group of Prof. Michael Hall from the Biozentrum of the University of Basel has shed light on the role of hepatic mTORC1 in whole body and the relevance for human liver cancers.

Hepatic mTORC1 controls whole body physiology

In mammals, the liver is a key organ that controls whole body physiology in response to nutrients. Hall's team investigated the role of the nutrient sensor mTORC1 in this process. The researchers were able to show that activation of mTORC1 in the liver of mice reduces not only hepatic but also locomotor activity and body temperature. Upon investigating the underlying molecular mechanism, they observed that mTORC1 hyperactivation enhances the level of the stress hormone FGF21 by depletion of the amino acid glutamine. Treatment of animals with glutamine reduced the level of FGF21 and thus prevented the physiological impairments.

Cancer treatment with mTORC1 inhibitors

Human cancers often exhibit aberrant mTORC1 signaling and glutamine addiction. "We were excited to see that in human tumors mTORC1 signaling correlates with FGF21 expression", comments cell biologist Dr. Marion Cornu and first author of the study. Moreover, mTORC1 inhibitors such as rapamycin are currently used as immunosuppressive agents and anti-cancer drugs. Thus, the novel findings of Hall's team provide evidence that treatment of glutamine addicted human cancers with rapamycin might have beneficial effects by blocking tumor growth and by preventing deregulation of whole body physiology.

More information: Marion Cornu, Wolfgang Oppliger, Verena Albert, Aaron M. Robitaille, Francesca Trapani, Luca Quagliata, Tobias Fuhrer, Uwe Sauer, Luigi Terracciano, Michael N. Hall , Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21 , PNAS; published online 31 July 2014 DOI: 10.1073/pnas.1412047111

add to favorites email to friend print save as pdf

Related Stories

New study explains duality of longevity drug rapamycin

Mar 29, 2012

A Penn- and MIT-led team explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend ...

Uncleaned cells mean weak muscles

Apr 23, 2013

The protein complex mTORC1 promotes muscle growth. However, should this complex remain constantly active, it impairs the ability of the cells to self-clean, causing myopathy. Scientists working with Markus ...

A protein provides stress relief for cells

Aug 19, 2013

German researchers have shown a new mechanism via which cells defend themselves against stress. Dr. Kathrin Thedieck and Birgit Holzwarth from the Institute of Biology III and the Cluster of Excellence BIOSS ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.